title: Essential thrombocythaemia.
authors.forename: George
authors.initials: G
authors.lastname: Double
authors.forename: Claire
authors.initials: C
authors.lastname: Harrison
mesh_terms: D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D037282:Calreticulin / Q000235:genetics; D015870:Gene Expression; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics; D009154:Mutation; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D053628:Receptors, Thrombopoietin / Q000235:genetics; D012307:Risk Factors; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; C576483:CALR protein, human; D037282:Calreticulin; D007155:Immunologic Factors; D016898:Interferon-alpha; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C021139:anagrelide; D006918:Hydroxyurea